Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negativeHBcAb-positive: A multicenter retrospective study

European Journal of Haematology

Volumn 85, Issue 3, 2010, Pages 243-250

  Ji, Dongmei ^a,b   Cao, Junning ^a,b   Hong, Xiaonan ^a,b   Li, Junmin ^c   Wang, Jianmin ^d   Chen, Fangyuan ^e   Wang, Chun ^f   Zou, Shanhua ^f  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

^e SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^f SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

Author keywords

HBcAb positive; HBsAg negative; hepatitis B virus reactivation; lymphoma; rituximab

Indexed keywords

ANTIVIRUS AGENT; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ANTIVIRAL THERAPY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INFECTION RISK; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PATIENT SELECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEROLOGY; UNIVERSITY HOSPITAL; VIRUS REACTIVATION; ADULT; AGED; CLINICAL TRIAL; DRUG EFFECTS; FEMALE; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; ISOLATION AND PURIFICATION; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MULTICENTER STUDY; RISK FACTOR; VIROLOGY; VIRUS ACTIVATION; VIRUS LATENCY; YOUNG ADULT;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; VIRUS ACTIVATION; VIRUS LATENCY; YOUNG ADULT;

EID: 77955784928     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2010.01474.x     Document Type: Article

References (22)

1. Lee W. Hepatitis B virus infection. N Engl J Med 1997 337 : 1733 45.
2. http://www.moh.gov.cn/publicfiles/business/htmlfiles/mohbgt/s3582/200804/ 33253.htm
3. Cheng AL, Hsiung CA, Su IJ, et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 2003 37 : 1320 8.
4. Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, Hui P, Leung NW, Zee B, Johnson PJ. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000 62 : 299 307.
5. Nakamura Y, Motokura T, Fujita A, Yamashita T, Ogata E. Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987-1991. Cancer 1996 78 : 2210 5.
6. Leaw SJ, Yen CJ, Huang WT, Chen TY, Su WC, Tsao CJ. Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. Ann Hematol 2004 83 : 270 5.
7. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002 346 : 235 42.
8. Pfreundschuh M, Trümper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006 7 : 379 91.
9. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006 24 : 3121 7.
10. Tsutsumi Y, Kawamura T, Saitoh S, et al. Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy. Leuk Lymphoma 2004 45 : 627 9.
11. Tsutsumi Y, Kanamori H, Mori A, Tanaka J, Asaka M, Imamura M, Masauzi N. Reactivation of hepatitis B virus with rituximab. Expert Opin Drug Saf 2005 4 : 599 608.
12. He YF, Li YH, Wang FH, et al. The effectiveness of lamivudine in preventing hepatitis B viral reactivation in rituximab-containing regimen for lymphoma. Ann Hematol 2008 87 : 481 5.
13. Yeo W, Chan TC, Leung NW, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009 27 : 605 11.
14. Targhetta C, Cabras MG, Mamusa AM, Mascia G, Angelucci E. Hepatitis B virus-related liver disease in isolated anti-hepatitis B-core positive lymphoma patients receiving chemo- or chemo-immune therapy. Haematologica 2008 93 : 951 2.
15. Koo YX, Tan DS, Tao M, Chow WC, Lim ST. Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy. Cancer 2010 116 : 115 21.
16. Fukushima N, Mizuta T, Tanaka M, et al. Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier. Ann Oncol 2009 20 : 2013 7.
17. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991 100 : 182 8.
18. Yeo W, Chan PK, Ho WM, et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004 22 : 927 34.
19. Wang F, Xu RH, Han B, Shi XY, Luo HY, Jiang WQ, Lin TY, Huang HQ, Xia ZJ, Guan ZZ. High incidence of hepatitis B virus infection in B-cell subtype non-Hodgkin lymphoma compared with other cancers. Cancer 2007 109 : 1360 4.
20. Pei SN, Chen CH, Lee CM, Wang MC, Ma MC, Hu TH, Kuo CY. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol 2010 89 : 255 62.
21. Al-Mekhaizeem KA, Miriello M, Sherker AH. The frequency and significance of isolated hepatitis B core antibody and the suggested management of patients. CMAJ 2001 165 : 1063 4.
22. http://www.nccn.org/professional/physician-gls/PDF/nhl.pdf